Literature DB >> 20546940

Binding of recombinant T cell receptor ligands (RTL) to antigen presenting cells prevents upregulation of CD11b and inhibits T cell activation and transfer of experimental autoimmune encephalomyelitis.

Sushmita Sinha1, Lisa Miller, Sandhya Subramanian, Owen J T McCarty, Thomas Proctor, Roberto Meza-Romero, Jianya Huan, Gregory G Burrows, Arthur A Vandenbark, Halina Offner.   

Abstract

Recombinant T cell ligands (RTLs) ameliorate experimental autoimmune encephalomyelitis (EAE) in an antigen-specific manner. We evaluated effects of RTL401 (I-A(s) alpha1beta1+PLP-139-151) on splenocytes from SJL/J mice with EAE to study RTL-T cell tolerance-inducing mechanisms. RTLs bound to B, macrophages and DCs, through RTL-MHC-alpha1beta1 moiety. RTL binding reduced CD11b expression on splenic macrophages/DC, and RTL401-conditioned macrophages/DC, not B cells, inhibited T cell activation. Reduced ability of RTL- incubated splenocytes to transfer EAE was likely mediated through macrophages/DC, since B cells were unnecessary for RTL treatment of EAE. These results demonstrate a novel pathway of T cell regulation by RTL-bound APCs. Copyright 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20546940      PMCID: PMC2924959          DOI: 10.1016/j.jneuroim.2010.04.013

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  21 in total

1.  Design, engineering and production of functional single-chain T cell receptor ligands.

Authors:  G G Burrows; J W Chang; H P Bächinger; D N Bourdette; H Offner; A A Vandenbark
Journal:  Protein Eng       Date:  1999-09

2.  Monomeric DR2/MOG-35-55 recombinant TCR ligand treats relapses of experimental encephalomyelitis in DR2 transgenic mice.

Authors:  Jason M Link; Cathleen M Rich; Maya Korat; Gregory G Burrows; Halina Offner; Arthur A Vandenbark
Journal:  Clin Immunol       Date:  2007-01-24       Impact factor: 3.969

Review 3.  Ligand recognition by alpha beta T cell receptors.

Authors:  M M Davis; J J Boniface; Z Reich; D Lyons; J Hampl; B Arden; Y Chien
Journal:  Annu Rev Immunol       Date:  1998       Impact factor: 28.527

4.  Antigen-specific therapy promotes repair of myelin and axonal damage in established EAE.

Authors:  Chunhe Wang; Bruce G Gold; Laurie J Kaler; Xiaolin Yu; Michael E Afentoulis; Gregory G Burrows; Arthur A Vandenbark; Dennis N Bourdette; Halina Offner
Journal:  J Neurochem       Date:  2006-08-03       Impact factor: 5.372

Review 5.  Role of macrophages/microglia in multiple sclerosis and experimental allergic encephalomyelitis.

Authors:  E N Benveniste
Journal:  J Mol Med (Berl)       Date:  1997-03       Impact factor: 4.599

6.  Critical requirement of CD11b (Mac-1) on T cells and accessory cells for development of experimental autoimmune encephalomyelitis.

Authors:  Daniel C Bullard; Xianzhen Hu; Trenton R Schoeb; Robert C Axtell; Chander Raman; Scott R Barnum
Journal:  J Immunol       Date:  2005-11-15       Impact factor: 5.422

7.  Treatment of passive experimental autoimmune encephalomyelitis in SJL mice with a recombinant TCR ligand induces IL-13 and prevents axonal injury.

Authors:  Halina Offner; Sandhya Subramanian; Chunhe Wang; Michael Afentoulis; Arthur A Vandenbark; Jianya Huan; Gregory G Burrows
Journal:  J Immunol       Date:  2005-09-15       Impact factor: 5.422

8.  A novel flow cytometric assay of human whole blood neutrophil and monocyte CD11b levels: upregulation by chemokines is related to receptor expression, comparison with neutrophil shape change, and effects of a chemokine receptor (CXCR2) antagonist.

Authors:  Grant C Nicholson; Rachel C Tennant; Donald C Carpenter; Henry M Sarau; Onn Min Kon; Peter J Barnes; Michael Salmon; Rupert S Vessey; Ruth Tal-Singer; Trevor T Hansel
Journal:  Pulm Pharmacol Ther       Date:  2006-01-06       Impact factor: 3.410

9.  Two-domain MHC class II molecules form stable complexes with myelin basic protein 69-89 peptide that detect and inhibit rat encephalitogenic T cells and treat experimental autoimmune encephalomyelitis.

Authors:  G G Burrows; B F Bebo; K L Adlard; A A Vandenbark; H Offner
Journal:  J Immunol       Date:  1998-12-01       Impact factor: 5.422

10.  A promising therapeutic approach for multiple sclerosis: recombinant T-cell receptor ligands modulate experimental autoimmune encephalomyelitis by reducing interleukin-17 production and inhibiting migration of encephalitogenic cells into the CNS.

Authors:  Sushmita Sinha; Sandhya Subramanian; Thomas M Proctor; Laurie J Kaler; Marjorie Grafe; Rony Dahan; Jianya Huan; Arthur A Vandenbark; Gregory G Burrows; Halina Offner
Journal:  J Neurosci       Date:  2007-11-14       Impact factor: 6.167

View more
  20 in total

1.  HLA-DRα1 constructs block CD74 expression and MIF effects in experimental autoimmune encephalomyelitis.

Authors:  Roberto Meza-Romero; Gil Benedek; Xiaolin Yu; Jeffery L Mooney; Rony Dahan; Nerri Duvshani; Richard Bucala; Halina Offner; Yoram Reiter; Gregory G Burrows; Arthur A Vandenbark
Journal:  J Immunol       Date:  2014-03-28       Impact factor: 5.422

2.  Extended culture of macrophages from different sources and maturation results in a common M2 phenotype.

Authors:  Lisa M Chamberlain; Dolly Holt-Casper; Mercedes Gonzalez-Juarrero; David W Grainger
Journal:  J Biomed Mater Res A       Date:  2015-02-27       Impact factor: 4.396

3.  A novel regulatory pathway for autoimmune disease: binding of partial MHC class II constructs to monocytes reduces CD74 expression and induces both specific and bystander T-cell tolerance.

Authors:  Arthur A Vandenbark; Roberto Meza-Romero; Gil Benedek; Shayne Andrew; Jianya Huan; Yuan K Chou; Abigail C Buenafe; Rony Dahan; Yoram Reiter; Jeffery L Mooney; Halina Offner; Gregory G Burrows
Journal:  J Autoimmun       Date:  2012-09-29       Impact factor: 7.094

4.  Gilt required for RTL550-CYS-MOG to treat experimental autoimmune encephalomyelitis.

Authors:  Gregory G Burrows; Roberto Meza-Romero; Jianya Huan; Sushmita Sinha; Jeffrey L Mooney; Arthur A Vandenbark; Halina Offner
Journal:  Metab Brain Dis       Date:  2012-03-07       Impact factor: 3.584

5.  Upregulation of CD74 and its potential association with disease severity in subjects with ischemic stroke.

Authors:  Liu Yang; Ying Kong; Honglei Ren; Minshu Li; Chang-Juan Wei; Elaine Shi; Wei-Na Jin; Junwei Hao; Arthur A Vandenbark; Halina Offner
Journal:  Neurochem Int       Date:  2016-11-21       Impact factor: 3.921

Review 6.  Partial MHC class II constructs as novel immunomodulatory therapy for stroke.

Authors:  Gil Benedek; Arthur A Vandenbark; Nabil J Alkayed; Halina Offner
Journal:  Neurochem Int       Date:  2016-10-31       Impact factor: 3.921

7.  RTL therapy for multiple sclerosis: a Phase I clinical study.

Authors:  Halina Offner; Sushmita Sinha; Gregory G Burrows; Adolph J Ferro; Arthur A Vandenbark
Journal:  J Neuroimmunol       Date:  2010-10-20       Impact factor: 3.478

8.  TCR-like antibodies distinguish conformational and functional differences in two- versus four-domain auto reactive MHC class II-peptide complexes.

Authors:  Rony Dahan; Moran Tabul; Yuan K Chou; Roberto Meza-Romero; Shayne Andrew; Adolph J Ferro; Gregory G Burrows; Halina Offner; Arthur A Vandenbark; Yoram Reiter
Journal:  Eur J Immunol       Date:  2011-04-12       Impact factor: 5.532

9.  Characterization of human platelet binding of recombinant T cell receptor ligand.

Authors:  Asako Itakura; Joseph E Aslan; Sushmita Sinha; Tara C White-Adams; Ishan A Patel; Roberto Meza-Romero; Arthur A Vandenbark; Gregory G Burrows; Halina Offner; Owen Jt McCarty
Journal:  J Neuroinflammation       Date:  2010-11-08       Impact factor: 8.322

10.  Accumulation of FLT3(+) CD11c (+) dendritic cells in psoriatic lesions and the anti-psoriatic effect of a selective FLT3 inhibitor.

Authors:  Heng-Xiu Yan; Wei-Wei Li; Yan Zhang; Xia-Wei Wei; Li-Xin Fu; Guo-Bo Shen; Tao Yin; Xiu-Ying Li; Hua-Shan Shi; Yang Wan; Qing-Yin Zhang; Jiong Li; Sheng-Yong Yang; Yu-Quan Wei
Journal:  Immunol Res       Date:  2014-10       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.